DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson’s disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of beta amyloid in the brain; and Vizamyl for early diagnosis of beta amyloid in Alzheimer's disease. The company also offers FES, a solution for diagnosis of metastatic breast cancer and determination of estrogen receptor status; FACBC for prostate cancer diagnosis; FDG for the diagnosis of tumors; and NaF for the diagnosis of bone-related diseases. DuChemBIO Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.
Metrics to compare | 176750 | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship Relationship176750PeersSector | |
---|---|---|---|---|
P/E Ratio | 39.3x | −4.6x | −0.5x | |
PEG Ratio | - | 0.01 | 0.00 | |
Price/Book | 6.9x | 1.5x | 2.6x | |
Price / LTM Sales | 8.4x | 2.4x | 3.3x | |
Upside (Analyst Target) | 37.6% | 39.6% | 43.4% | |
Fair Value Upside | Unlock | 8.0% | 7.1% | Unlock |